title: MiRNA-141 and miRNA-200b are closely related to invasive ability and considered as decision-making biomarkers for the extent of PLND during cystectomy.
abstract: BACKGROUND
  MicroRNAs (miRNAs) are small non-coding RNAs that silence their cognate target genes by specifically binding and cleaving messenger RNAs or inhibiting their translation. In this study, we explored whether miRNA-141 and miRNA-200b are involved in regulation of the invasive ability and epithelial-mesenchymal transition (EMT) of bladder cancer cells in vitro. We also evaluated their potential as biomarkers for deciding the extent of pelvic lymph node dissection (PLND) required during radical cystectomy.
  
  
  METHODS
  Pri- and anti-miR cell lines were constructed. The invasive capacity of the cells was tested using a cell invasion assay. The MMP-2, MMP-9 and EMT-related markers were validated through Western blotting analysis. Seventy-eight urine samples from patients undergoing cystectomy and super-extended lymph node dissection were evaluated by qRT-PCR.
  
  
  RESULTS
  Loss of expression of miRNA-141 and miRNA-200b was associated with increased invasion and migration ability, upregulated MMP-2, MMP-9, vimentin and N-cadherin expression, and downregulated E-cadherin expression in bladder cancer cell lines. Urine miRNA-141 and miRNA-200b levels could discriminate patients with lymph node metastasis from those who were lymph node negative (AUC: 0.704 and 0.674, respectively).
  
  
  CONCLUSIONS
  MiRNA-141 and miRNA-200b play important roles in the invasive ability and EMT phenotype of bladder cancer. Detection of miRNA-141 and miRNA-200b can help to identify patients undergoing cystectomy who are likely to have lymph node metastasis, and therefore those who may benefit from super-extended PLND.
authors.affiliation: Department of Urology, Xiangya Hospital, Central South University, No.87 Xiangya Road, Changsha City, Hunan Province, 410008, P. R. China. lwt_xy2yy@163.com.|Present address: Department of Urology, The second Xiangya Hospital, Central South University, Changsha City, Hunan Province, P. R. China. lwt_xy2yy@163.com.
authors.forename: Wentao
authors.initials: W
authors.lastname: Liu
authors.affiliation: Department of Urology, Xiangya Hospital, Central South University, No.87 Xiangya Road, Changsha City, Hunan Province, 410008, P. R. China. qilin_xyyy@163.com.
authors.forename: Lin
authors.initials: L
authors.lastname: Qi
authors.affiliation: Department of Pathology, Xiangya School of Medicine, Central South University, Changsha City, Hunan Province, P. R. China. huilv_xyyy@163.com.
authors.forename: Hui
authors.initials: H
authors.lastname: Lv
authors.affiliation: Department of Urology, Xiangya Hospital, Central South University, No.87 Xiangya Road, Changsha City, Hunan Province, 410008, P. R. China. zuxiongbing_xyyy@163.com.
authors.forename: Xiongbing
authors.initials: X
authors.lastname: Zu
authors.affiliation: Department of Urology, Xiangya Hospital, Central South University, No.87 Xiangya Road, Changsha City, Hunan Province, 410008, P. R. China. chenmf3232@163.com.
authors.forename: Minfeng
authors.initials: M
authors.lastname: Chen
authors.affiliation: Department of Urology, First Teaching Hospital, Zhengzhou University, Zhengzhou City, Henan Province, P. R. China. wangjun_xyyy@163.com.
authors.forename: Jun
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Urology, Xiangya Hospital, Central South University, No.87 Xiangya Road, Changsha City, Hunan Province, 410008, P. R. China. liulongfei_xyyy@163.com.
authors.forename: Longfei
authors.initials: L
authors.lastname: Liu
authors.affiliation: Department of Urology, Xiangya Hospital, Central South University, No.87 Xiangya Road, Changsha City, Hunan Province, 410008, P. R. China. zengfeng_xyyy@163.com.
authors.forename: Feng
authors.initials: F
authors.lastname: Zeng
authors.affiliation: Department of Urology, Xiangya Hospital, Central South University, No.87 Xiangya Road, Changsha City, Hunan Province, 410008, P. R. China. liyuan_xyyy@163.com.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers; D015820:Cadherins / Q000235:genetics / Q000378:metabolism; D045744:Cell Line, Tumor; D015653:Cystectomy; D058750:Epithelial-Mesenchymal Transition / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D016086:Lentivirus / Q000235:genetics; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000235:genetics / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000235:genetics / Q000378:metabolism; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D012372:ROC Curve; D014161:Transduction, Genetic; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000235:genetics* / Q000601:surgery; D014746:Vimentin / Q000235:genetics / Q000378:metabolism
chemical_list: D015415:Biomarkers; D015820:Cadherins; C533895:MIRN141 microRNA, human; C533896:MIRN200 microRNA, human; D035683:MicroRNAs; D014746:Vimentin; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9